Cannabis Schedule III: The Public-Participation Window for the June 29 DEA Hearing Closes This Week

The dates that matter this week

The DEA’s formal administrative-law-judge hearing on broader cannabis rescheduling begins June 29. Public-participation deadlines are now within days:

• May 20 (Wednesday) — written notice of intent to participate via mail
• May 24 (Sunday) — written notice of intent to participate via email
• May 28 — desired-participation submissions

The partial rescheduling took effect April 23 — that move was narrow, covering only FDA-approved cannabis products and products dispensed under qualifying state medical-cannabis licenses. The June 29 hearing decides whether to extend Schedule III to all forms of marijuana.

Three things on the table — and one that isn’t

What the hearing will decide: (1) whether cannabis as a whole meets the Controlled Substances Act criteria for Schedule III; (2) what the DEA’s evidentiary standard should be for that determination; (3) how state-licensed adult-use markets will or will not be affected if cannabis is moved to Schedule III as a class.

What the hearing will not decide: whether cannabis can be sold over the counter, whether existing state adult-use programs become federally legal, or whether interstate cannabis commerce becomes permissible. Schedule III is not legalization. It does meaningfully change the tax treatment (280E goes away for compliant operators), the research environment (Schedule I research barriers drop), and the federal posture on physician recommendations — but it does not collapse the existing state-by-state legal patchwork.

For the addiction-medicine community specifically, the open question is whether broader Schedule III rescheduling will accelerate research on cannabinoid hyperemesis syndrome, cannabis-induced psychosis risk in adolescents, and CUD pharmacotherapy — three areas where Schedule I has been a persistent research bottleneck. We covered the cannabis-psychiatric link in early May; the Schedule III change, if it lands as expected, makes more of that research finally possible.

Who is participating

Gibson Dunn’s tracker lists more than 60 organizations that have either filed or signaled intent to file — major multistate operators, the Cannabis Regulators Association, NORML, the National Association of State Treatment Court Professionals, several state attorneys general, and a coalition of addiction-medicine researchers. SAMHSA has not commented publicly on its own participation. Rize is not filing a position; we will cover the proceedings as they happen.